CAR T-cell therapy re-engineers immune cells to target and eradicate high-risk blood cancers, offering potential cures where traditional chemotherapy fails. Initially requiring inpatient care due to ...

The CAR T-cell therapy market is ripe for growth with over 250 companies and 500 drugs in development globally. Key opportunities lie in targeting hematologic malignancies and overcoming challenges in ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

CAR T-cell therapy has revolutionized treatment for many blood cancers. However, the benefits of its use in the early stages of care remain uncertain. Chimeric antigen receptor (CAR) T-cell therapy ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

CAR-T cell therapy has cured some children with blood cancers and is being studied in solid tumors, where responses differ due to how these cancers grow. CAR-T cell therapy has cured some children ...

CAR-T is a powerful tool which is still evolving. Here we highlight what is new in CAR-T cell therapy Cancer cells often play hide-and-seek with the immune system in an attempt to evade catastrophic ...

CAR T-cell therapy is a personalized treatment that uses a patient’s own immune cells to fight cancer, making it effective but unsuitable for mass production, which increases the cost. The complex ...

According to MarketsandMarkets™, the CAR T-Cell Therapy Market is estimated to reach USD 13.78 billion by 2031 from USD 7.24 billion in 2026, at a CAGR of 13.7%.

Dr. John Mellors, who heads the cell therapy discovery team for biotechnology company Galapagos, talks about the innovations the organization is making to improve delivery speed and access to CAR ...